Skip to content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature

  • 1Email author,
  • 1, 2,
  • 3,
  • 3,
  • 4,
  • 4,
  • 5,
  • 6 and
  • 3
Journal of Medical Case Reports201913:88

https://doi.org/10.1186/s13256-019-2002-2

  • Received: 6 June 2018
  • Accepted: 29 January 2019
  • Published:
Open Peer Review reports

Abstract

Introduction

Immune checkpoint inhibitors are a promising class of anticancer drugs. The clinical benefits afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events that affect multiple organs, and endocrine immune-related adverse events include thyroiditis and hypophysitis. Hypophysitis is less frequent and has a less severe clinical presentation in patients treated with other immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, than in those treated with ipilimumab. However, studies have described isolated adrenocorticotropic hormone deficiency cases associated with nivolumab, pembrolizumab, and atezolizumab therapy, most of which occurred during the course of immune checkpoint inhibitor therapy. We report a rare case of patient with isolated adrenocorticotropic hormone deficiency that occurred after nivolumab therapy.

Case presentation

A 69-year-old Japanese woman with advanced lung adenocarcinoma developed painless thyroiditis with transient elevations of serum thyroid hormones during 3 months of cancer treatment with nivolumab and began thyroid hormone replacement therapy for subsequent primary hypothyroidism. Four months after nivolumab therapy was discontinued, she developed isolated adrenocorticotropic hormone deficiency; corticosteroid replacement therapy relieved her secondary adrenal insufficiency symptoms, such as anorexia and fatigue. Human leukocyte antigen typing revealed the presence of DRB1*04:05-DQB1*04:01-DQA1*03:03 and DRB1*09:01-DQB1*03:03-DQA1*03:02 haplotypes, which increase susceptibility to autoimmune polyendocrine syndrome associated with thyroid and pituitary disorders in the Japanese population.

Conclusions

Our patient developed thyroiditis during cancer treatment with nivolumab and subsequently exhibited isolated adrenocorticotropic hormone deficiency 4 months after discontinuing the drug. Administration of nivolumab in combination with a genetic predisposition to polyglandular autoimmunity probably caused both the thyroiditis and hypophysitis, resulting in primary hypothyroidism and isolated adrenocorticotropic hormone deficiency, respectively, in our patient. The present case highlights the need for physicians to be aware that endocrine immune-related adverse events, including hypophysitis, can occur more than several months after discontinuing a drug.

Keywords

  • Human leukocyte antigen
  • Hydrocortisone
  • Isolated adrenocorticotropic hormone deficiency
  • Lung adenocarcinoma
  • Nivolumab
  • Thyroiditis

Introduction

Immune checkpoint inhibitors (ICIs) are a promising new class of anticancer drugs that reactivate cytotoxic T cells which, in turn, destroy tumor cells [1]. Because ICIs generate dysimmune toxicities (autoimmunity) by creating an imbalance within the immune system, the clinical benefits afforded by ICIs can be accompanied by immune-related adverse events (IRAEs) that affect multiple organs, mainly the skin, gut, liver, lung, and endocrine tissues [2]. Common endocrine IRAEs include thyroiditis and hypophysitis, whereas uncommon IRAEs include adrenalitis and type 1 diabetes mellitus [3].

Compared with those treated with ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 monoclonal antibody, hypophysitis is less frequent and has a less severe clinical presentation in patients treated with other ICIs, such as nivolumab and pembrolizumab, which are anti-programmed cell death protein 1 (PD-1) monoclonal antibodies, and atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody [46]. However, studies have described isolated adrenocorticotropic hormone deficiency (IAD) cases associated with nivolumab, pembrolizumab, and atezolizumab therapy [722], most of which have occurred during the course of ICI therapy.

IAD is a pituitary disorder characterized by secondary adrenal insufficiency (AI) with low or absent cortisol production but normal secretion of pituitary hormones other than adrenocorticotropic hormone (ACTH) [23]. Patients with IAD typically present with anorexia, fatigue, and general weakness, but corticosteroid replacement therapy is effective for managing this disorder.

We report a case of a patient with advanced lung adenocarcinoma (LAC) who developed thyroiditis during nivolumab therapy and subsequently exhibited IAD 4 months after the discontinuation of nivolumab. We also review previously reported cases of nivolumab-related thyroiditis and IAD.

Case presentation

A 69-year-old Japanese woman who had been undergoing cancer treatment for advanced LAC was admitted to our hospital in January 2018 because of anorexia, fatigue, and general weakness. The patient had a maternal family history of esophageal cancer. The patient had been a housewife since her 20s, had never smoked cigarettes, and did not have a drinking habit. The patient’s medical history was unremarkable until June 2016, when an abnormal x-ray shadow was found in her right lung. A computed tomographic (CT) scan revealed a tumor (3.1 cm) in the upper lobe of her right lung (Fig. 1a), right hilar and mediastinal lymph node swellings, and liver tumors. A transbronchoscopic biopsy from the lung tumor revealed LAC with vascular invasion (Fig. 2). IHC revealed no anaplastic lymphoma kinase rearrangement, and a genetic analysis of the cancer cells detected no epidermal growth factor receptor mutation. Whole-body technetium-99m methylene diphosphonate scintigraphy revealed multiple lesions at the thoracic and lumbar vertebrae, sternum, ilium, and right ischial bones. Brain magnetic resonance imaging (MRI) revealed tumors in the left temporal lobe and right cerebellar hemisphere (Fig. 1b). As a result, the patient was diagnosed with LAC with distant metastases to the brain, liver, and bones (cT2aN2M1b, stage IV) [24].
Fig. 1
Fig. 1

Radiological findings (July 2016). a Chest computed tomographic scan showing a tumor (3.1 cm) in the upper lobe of the right lung (arrow). b T1-weighted transverse magnetic resonance imaging of the brain showing a tumor in the left temporal lobe (arrow) and a tumor in the right cerebellar hemisphere (short arrow)

Fig. 2
Fig. 2

Histopathological findings of biopsy specimen from the left lung tumor (July 2016). a, b Microscopic examination showing bronchial mucosal infiltration by poorly differentiated lung adenocarcinoma (a), and vascular invasion is seen (arrows) (b) (H&E staining). c, d The cytoplasm of the tumor cells was immunohistochemically positive for surfactant protein A (c), and the tumor cell nuclei were positive for thyroid transcription factor 1 (d). Ly Lymph duct, V Vein

The patient underwent stereotactic radiation surgery (total, 22 Gy) for her metastatic brain tumors in July 2016. Thereafter, she received four courses of chemotherapy with intravenous cisplatin, pemetrexed, and bevacizumab from July 2016 to October 2016; this treatment regimen effectively controlled her advanced LAC with a Response Evaluation Criteria in Solid Tumors (RECIST) classification of partial response [25]. The patient subsequently received nine courses of maintenance chemotherapy with intravenous pemetrexed and bevacizumab from November 2016 to April 2017. CT scans performed in May 2017 revealed no progression of the primary LAC or metastatic brain and bone lesions, but they showed evidence of progression of the metastatic liver tumors.

Subsequently, the patient began second-line chemotherapy with intravenous nivolumab (133 mg [3 mg/kg] every 2 weeks) in May 2017 (Fig. 3). Thyroid function was routinely monitored in July 2017 after five courses of nivolumab therapy, and she showed high levels of serum free thyroxine (FT4, 1.91 ng/dl) and low levels of thyroid-stimulating hormone (TSH, 0.04 μIU/ml). The patient had no symptoms of thyrotoxicosis or exophthalmos but had mild and soft struma without any pain or fever. Ultrasonography revealed rough and mildly low echogenicity in a slightly enlarged thyroid gland without a tumor (Fig. 4a, b), and technetium-99m pertechnetate thyroid scintigraphy revealed a low thyroid uptake of 0.1% (reference range, 0.5–4%) in the entire thyroid gland (Fig. 4c). The patient had negative test results for TSH-binding inhibitory immunoglobulin (TBII), thyroglobulin autoantibody (TgAb), and thyroid peroxidase autoantibody (TPOAb). On the basis of these findings, she was diagnosed with painless thyroiditis induced by nivolumab and was closely followed without medication. The patient exhibited primary hypothyroidism (FT4, 0.66 ng/dl; TSH, 11.41 μIU/ml) in September 2017 and initiated thyroid hormone replacement therapy with oral levothyroxine (50 μg/day).
Fig. 3
Fig. 3

Clinical course of the patient before the onset of isolated adrenocorticotropic hormone deficiency. Bmab Bevacizumab, CDDP Cisplatin, DTX Docetaxel, FT4 Free thyroxine, IAD Isolated adrenocorticotropic hormone deficiency, PEM Pemetrexed, Rmab Ramucirumab, TSH Thyroid-stimulating hormone

Fig. 4
Fig. 4

Thyroid gland imaging findings (July 2017). a, b Ultrasonography of the thyroid gland showing rough and mildly low echogenicity in a slightly enlarged thyroid gland without a tumor (a). Color Doppler images revealed no increased blood flow in the thyroid gland (b). c Technetium-99m pertechnetate thyroid scintigraphy showing a low thyroid uptake (0.1%, reference range 0.5–4%) in the entire thyroid gland without a hot spot

Because the CT scans performed after the sixth cycle of nivolumab revealed enlargements of the metastatic liver tumors, nivolumab therapy was discontinued in August 2017. The patient received three courses of third-line chemotherapy with docetaxel and ramucirumab beginning in September 2017, which effectively controlled her LAC (RECIST classification of partial response), but this treatment was terminated in October 2017 because of side effects, such as joint pain and rhabdomyolysis. The patient did not consent to continue anticancer drug therapy after considering the potential benefits and side effects, and she chose to receive best supportive care.

In November 2017, the patient’s body weight, blood pressure, and pulse rate were 45 kg, 121/67 mmHg, and 76 beats per minute, respectively. She had normal levels of serum electrolytes (sodium 140 mEq/L, potassium 4.3 mEq/L, and chloride 106 mEq/L). However, the patient developed acute anorexia, fatigue, and general weakness in December 2017 and was admitted to the Department of Respiratory Medicine at our hospital in January 2018.

On admission, the patient had clear consciousness and did not complain of headache, abdominal pain, diarrhea, or joint and muscle pain. Her height, body weight, body temperature, blood pressure, and pulse rate were 153 cm, 38 kg, 36.9 °C, 90/54 mmHg, and 73 beats per minute, respectively. She had mild and soft goiter without pain. No heart murmur, chest rales, rash, vitiligo, skin pigmentation, or peripheral edema was detected. No paralysis, cerebellar ataxia, pyramidal or extrapyramidal tract symptoms, visual disturbance, hearing loss, dysarthria, or epileptic seizures were found. A blood analysis revealed hyponatremia (serum sodium 124 mEq/L); asymptomatic hypoglycemia (fasting plasma glucose 65 mg/dl); and low levels of immunoreactive insulin (< 0.2 μU/ml), ACTH (2.6 pg/ml), and cortisol (< 0.2 μg/dl) (Table 1). Because AI was suspected, oral levothyroxine was discontinued on day 2 of admission because hormone replacement therapy with thyroid hormone alone can exaggerate AI symptoms when hypothyroidism and AI coexist. The patient was referred to the Department of Endocrinology and Metabolism on day 5 of admission.
Table 1

Laboratory findings at admission (January 2018)

Hematology

 Red blood cells

379 × 104/μl

(386–492)

 Hemoglobin

11.3 g/dl

(11.6–14.8)

 Hematocrit

33.7%

(35.1–44.4)

 White blood cells

3600/μl

(3300–8600)

 Platelets

20.9 × 104/μl

(15.8–34.8)

Blood chemistry

 Fasting plasma glucose

65 mg/dl

(70–109)

 Immunoreactive insulin

< 0.2 μU/ml

(2.2–12.4)

 Glycated hemoglobin

5.2%

(4.6–6.2)

 Total cholesterol

161 mg/dl

(142–248)

 Triglycerides

62 mg/dl

(30–117)

 Total protein

6.2 g/dl

(6.6–8.1)

 Albumin

3.7 g/dl

(4.1–5.1)

 Aspartate aminotransferase

31 IU/L

(13–30)

 Alanine aminotransferase

12 IU/L

(7–23)

 Creatine phosphokinase

59 IU/L

(41–153)

 Urea nitrogen

11.4 mg/dl

(8.0–18.4)

 Creatinine

0.66 mg/dl

(0.46–0.79)

 Uric acid

2.5 mg/dl

(2.6–5.5)

 Sodium

124 mEq/L

(137–147)

 Potassium

4.8 mEq/L

(3.5–4.7)

 Chloride

90 mEq/L

(98–108)

 Calcium

8.7 mg/dl

(8.8–10.1)

 C-reactive protein

0.16 mg/dl

(0–0.14)

 Immunoglobulin G4

35 mg/dl

(5–117)

 Carcinoembryonic antigen

208.0 ng/ml

(0–4.76)

 Sialyl-Lewis X

26.6 U/ml

(0–37.9)

 Cytokeratin 19 fragments

1.6 ng/ml

(0–2.1)

 Squamous cell carcinoma antigen

1.1 ng/ml

(0–1.5)

 Plasma osmolality

254 mOsm/L

(275–290)

 Arginine vasopressin

1.0 pg/ml

 

 Thyroid-stimulating hormone

4.84 μIU/ml

(0.50–5.00)

 Free thyroxine

1.44 ng/dl

(0.90–1.70)

 Free triiodothyronine

3.22 pg/ml

(2.30–4.00)

 Adrenocorticotropic hormone

2.6 pg/ml

(7.2–63.3)

 Serum cortisol

< 0.2 μg/dl

(4.5–21.1)

 Dehydroepiandrosterone sulfate

< 20 ng/ml

(120–1330)

 Plasma renin activity

0.2 ng/ml/h

(0.2–2.3)

 Aldosterone

8.8 ng/dl

(3.0–15.9)

The reference range for each parameter is shown in parentheses

Blood samples were taken in the morning (10 a.m.) with the patient in supine position. The patient was taking thyroid hormone replacement therapy with oral levothyroxine (50 μg/day) for primary hypothyroidism

A rapid cosyntropin stimulation test suggested secondary AI (Table 2). Dynamic tests assessing the secretion of pituitary hormones showed the normal release of growth hormone (GH), TSH, and prolactin; age-appropriate release of luteinizing hormone and follicle-stimulating hormone; but no ACTH release following a corticotropin-releasing hormone load (Table 3). A GH-releasing peptide 2 loading test also showed no ACTH release, whereas GH release was sufficient (Table 4). These findings were indicative of IAD. A brain MRI study revealed slight atrophy of the anterior pituitary with a pituitary height of 2.2 mm (Fig. 5).
Table 2

Endocrinological investigation: rapid cosyntropin stimulation test in January 2018 (day 6 after admission)

 

Time (min)

0

30

60

Cortisol (μg/dl)

< 0.2

1.0

1.4

Aldosterone

5.7

14.1

16.5

Blood samples were taken at 0 (just before) and at 30 and 60 min after synthetic adrenocorticotropic hormone 1–24 (cosyntropin hydroxide 0.25 mg) was intravenously administered in the morning (9 a.m.). The patient had a low plasma adrenocorticotropic hormone level (2.3 pg/ml) and low plasma renin activity (< 0.2 ng/ml/h) just before cosyntropin administration

Table 3

Endocrinological investigation: CRH/GRF/TRH/LHRH stimulation test in January 2018 (day 7 after admission)

 

Time (min)

0

15

30

60

90

120

Adrenocorticotropic hormone (pg/ml)

2.1

3.5

4.0

3.4

2.9

2.2

Cortisol (μg/dl)

< 0.2

< 0.2

< 0.2

< 0.2

< 0.2

< 0.2

Thyroid-stimulating hormone (μIU/ml)

5.47

22.86

33.95

28.66

23.64

17.65

Growth hormone (ng/ml)

7.67

19.96

34.68

38.76

37.53

21.17

Prolactin (ng/ml)

22.6

75.6

94.4

84.6

61.2

44.6

Luteinizing hormone (mIU/ml)

10.4

21.8

30.9

45.3

47.9

43.1

Follicle-stimulating hormone (mIU/ml)

32.8

36.2

33.6

36.6

45.6

45.5

The following synthetic hypothalamic hormones were intravenously administered in the morning (9 a.m.): human corticotropin-releasing hormone (CRH; 100 μg), growth hormone-releasing factor (GRF; 100 μg), thyrotropin-releasing hormone (TRH; 500 μg), and luteinizing hormone-releasing hormone (LHRH; 100 μg)

The hormone replacement therapy with oral levothyroxine (50 μg/day) for primary hypothyroidism was discontinued on day 2 after admission, and the patient’s serum levels of free thyroxine (1.26 ng/dl) and free triiodothyronine (2.77 pg/ml) were measured just before the drug administration

Table 4

Endocrinological investigation: GHRP-2 stimulation test in January 2018 (day 8 after admission)

 

Time (min)

0

15

30

45

60

Adrenocorticotropic hormone (pg/ml)

1.9

2.3

1.9

1.9

3.2

Cortisol (μg/dl)

< 0.2

< 0.2

< 0.2

< 0.2

< 0.2

Growth hormone (ng/ml)

3.73

18.02

29.63

32.98

26.21

Growth hormone-releasing peptide (GHRP)-2 (100 μg) was intravenously administered in the morning (9 a.m.)

Fig. 5
Fig. 5

Magnetic resonance imaging of the pituitary gland (January 2018). a Sagittal T1-weighted plain magnetic resonance imaging (MRI) study showing normal high-intensity signals in the posterior lobe of the pituitary. b, c Gadolinium-enhanced MRI scans (b, sagittal plane; c, coronal plane) showing homogeneous enhancement of the normal hypophyseal stalk and mild atrophy of the anterior lobe of the pituitary gland. The width, length, and height of the pituitary gland are 16.2, 9.8, and 2.2 mm, respectively

The patient had negative test results for anti-pituitary cell antibody, TgAb, TPOAb, and TBII as well as other organ-specific autoantibodies, including glutamic acid decarboxylase autoantibody, insulin autoantibody, gastric parietal cell autoantibody, intrinsic factor autoantibody, adrenocortical autoantibody, antinuclear antibody, Sjögren’s syndrome A and B antibodies, anti-citrullinated peptide antibody, and rheumatoid factor.

Human leukocyte antigen (HLA) typing revealed the presence of A*08:01/12:02, B*48:01/52:01, and C*08:01/12:02 class I genes and DRB1*04:05/09:01, DQB1*03:03/04:01, DQA1*03:02/03:03, and DPB1*04:02/14:01 class II genes.

The patient began corticosteroid replacement therapy with oral hydrocortisone (15 mg/day) for AI secondary to IAD on the afternoon of day 8 of admission. Subsequently, she resumed oral levothyroxine (50 μg/day) for primary hypothyroidism on day 9 of admission.

The patient experienced improvements in anorexia, fatigue, and general weakness and became ambulatory within days. Her hyponatremia was corrected within 1 week, and her hypoglycemia was resolved. Laboratory data obtained on day 21 of admission showed normal levels of serum sodium (140 mEq/L), potassium (4.3 mEq/L), chloride (106 mEq/L), FT4 (1.60 ng/dl), TSH (3.28 μIU/ml), and fasting plasma glucose (78 mg/dl). The patient was discharged on day 25 of admission.

The subsequent clinical course of the patient was mostly uneventful for 6 months after discharge. As her LAC progressed, her ability to perform activities of daily living decreased, and in November 2018, she was transferred to a local hospital to receive terminal care.

Discussion

Our patient with advanced LAC developed painless thyroiditis associated with a transient elevation of serum thyroid hormones (thyrotoxicosis) during 3 months of second-line chemotherapy with nivolumab and began thyroid hormone replacement therapy for subsequent primary hypothyroidism. Four months after nivolumab therapy was discontinued, the patient developed IAD. Other than reports regarding nivolumab, there have been few reports on thyroid or pituitary dysfunction associated with the anticancer agents that our patient took, including bevacizumab and ramucirumab (Fig. 3) [2629]. External brain radiotherapy can produce pituitary dysfunction that is usually associated with GH deficiency, but it seldom causes IAD [30]. These findings suggest that our patient exhibited both ICI-related thyroiditis and IAD induced by nivolumab.

Table 5 summarizes the characteristics of reported patients who exhibited nivolumab-related thyroiditis and IAD [15, 16, 19, 20]. The cases describe both male and female adults with melanoma, LAC, or renal cell carcinoma. They developed thyroiditis that resulted in hypothyroidism and subsequently developed IAD.
Table 5.

Summary of reported patients who exhibited thyroiditis and isolated adrenocorticotropic hormone deficiency in association with cancer treatment with nivolumab

Ref.

Age/sex

Nivolumab

Thyroiditis

IAD

Other IRAEs

Target cancer

Regimen

Administration times (courses)

Time from first nivolumab administration to thyroiditis onset (months)

Thyroid function abnormality

Thyroid autoantibodies

Abnormality on thyroid ultrasonography

Time from first nivolumab administration to IAD onset (months)

Major symptoms

Pituitary autoantibodies

Morphological abnormality in the pituitary on MRI

[15]

60/M

LAC

3 mg/kg every 2 weeks

11

5

Hypothyroidism

N/D

N/D

7

Fatigue, anorexia, dizziness, gait instability

N/D

None

None

[16]

54/M

RCC

2 mg/kg every 2 weeks

12

3

Hypothyroidism

Positive (TgAb and TPOAb)

N/D

6

Fatigue, hypoglycemia

N/D

None

None

[19]

58/M

Melanoma

3 mg/kg every 2 weeks

N/D

4

Transient thyrotoxicosis and subsequent hypothyroidism

Positive (TgAb)

N/D

8

Fatigue, anorexia, weakness

N/D

None

Hypercalcemia

[20]

63/F

Melanoma

2 mg/kg every 3 weeks

8

6

Transient thyrotoxicosis and subsequent hypothyroidism

Positive (TgAb)

Low echogenicity

8

Fatigue

N/D

None

None

Present case

69/F

LAC

3 mg/kg every 2 weeks

6

2

Transient thyrotoxicosis and subsequent hypothyroidism

Negative

Low echogenicity

7

Fatigue, anorexia, weakness

Negative

Atrophy

None

F female, IAD isolated adrenocorticotropic hormone deficiency, IRAE immune-related adverse event, LAC lung adenocarcinoma, M male, MRI magnetic resonance imaging, N/D not described, RCC renal cell carcinoma, TgAb thyroglobulin autoantibody, TPOAb thyroid peroxidase autoantibody

Thyroiditis is the most frequent IRAE associated with endocrine organs, regardless of the different ICIs [3, 6]. Thyroiditis usually occurs within a few months of initiating ICI therapy with or without verifiable circulating thyroid autoantibodies, such as TgAb and TPOAb. Common clinical manifestations of ICI-related thyroiditis include painless thyroiditis characterized by a transient thyrotoxicosis and subsequent occurrence of persistent primary hypothyroidism [31, 32]. In our patient, physical findings, thyroid gland image findings (Fig. 4), and the clinical course (Fig. 3) indicated that she had a typical form of ICI-related thyroiditis.

Studies on patients with IAD associated with nivolumab have shown that the latency from initial nivolumab administration to IAD onset ranged approximately from 4 to 8 months, with a mean period of roughly 6 months [720], which appears to be longer than that of ipilimumab-related hypophysitis (approximately 2 months) [5]. Most cases of nivolumab-related IAD occurred during the course of or within 1 month of the discontinuation of nivolumab therapy [719], but one patient with melanoma who completed 6 months of nivolumab therapy 2 months prior developed IAD during subsequent ipilimumab therapy [20]. Similarly, our patient with LAC developed IAD 4 months after the discontinuation of 3 months of nivolumab therapy. Our patient’s case highlights the need for physicians to be aware that endocrine IRAEs, including hypophysitis, can occur more than several months after discontinuing a drug.

Patients with ipilimumab-related hypophysitis usually exhibit pituitary enlargement as radiological evidence of pituitary inflammation and pituitary dysfunction with multiple deficits in anterior pituitary hormones [4, 5, 33]. By contrast, many studies of nivolumab-related IAD have reported no morphological pituitary abnormalities [817, 19, 20], whereas two studies described patients who showed mild or slight but definitely reversible pituitary enlargement [7, 18]. However, there was a reported case of a patient with atezolizumab-related IAD who showed anterior pituitary atrophy [22]. Similarly, our patient exhibited mild anterior pituitary atrophy (Fig. 5).

Autoimmune polyendocrine syndromes (APS) are a heterogeneous group of endocrine and nonendocrine organ-specific autoimmune disorders [34]. For example, autoimmune thyroid diseases can be associated with other endocrine disorders as part of APS type 3. Genetic factors, including HLA class II genes, play a role in the development of APS. Our patient with ICI-related thyroiditis and IAD had the HLA-DRB1*04:05-DQB1*04:01-DQA1*03:03 and DRB1*09:01-DQB1*03:03-DQA1*03:02 haplotypes, which increase susceptibility to APS type 3 associated with pituitary disorders in the Japanese population [35]. These findings suggest that administration of nivolumab in combination with a genetic predisposition to polyglandular autoimmunity caused thyroiditis and hypophysitis in association with APS type 3, resulting in primary hypothyroidism and IAD, respectively, in our patient.

Conclusions

We describe a patient with advanced LAC who developed thyroiditis during 3 months of nivolumab therapy and subsequently exhibited IAD 4 months after the discontinuation of nivolumab. The combination of nivolumab administration and genetic factors that manifested a susceptibility to polyglandular autoimmunity likely caused her ICI-related thyroiditis and hypophysitis. Thus, physicians should be aware that ICI-related endocrinopathies, including hypophysitis, may occur more than several months after discontinuation of the drug.

Abbreviations

ACTH: 

Adrenocorticotropic hormone

AI: 

Adrenal insufficiency

APS: 

Autoimmune polyendocrine syndrome

Bmab: 

Bevacizumab

CDDP: 

Cisplatin

CRH: 

Corticotropin-releasing hormone

CT: 

Computed tomography

DTX: 

Docetaxel

F: 

Female

FT4

Free thyroxine

GH: 

Growth hormone

GHRP: 

Growth hormone-releasing peptide

GRF: 

Growth hormone-releasing factor

HLA: 

Human leukocyte antigen

IAD: 

Isolated adrenocorticotropic hormone deficiency

ICI: 

Immune checkpoint inhibitor

IRAE: 

Immune-related adverse event

LAC: 

Lung adenocarcinoma

LHRH: 

Luteinizing hormone-releasing hormone

Ly: 

Lymph duct

M: 

Male

MRI: 

Magnetic resonance imaging

N/D: 

Not described

PD-1: 

Anti-programmed cell death protein-1

PD-L1: 

Anti-programmed cell death ligand-1

PEM: 

Pemetrexed

RCC: 

Renal cell carcinoma

RECIST: 

Response Evaluation Criteria in Solid Tumors

Rmab: 

Ramucirumab

TBII: 

Thyroid-stimulating hormone-binding inhibitory immunoglobulin

TgAb: 

Thyroglobulin autoantibody

TPOAb: 

Thyroid peroxidase autoantibody

TRH: 

Thyrotropin-releasing hormone

TSH: 

Thyroid-stimulating hormone

V: 

Vein

Declarations

Acknowledgements

The authors thank the clinical laboratory technicians of Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, for their valuable technical support.

Funding

No sources of funding are declared for this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

NO, MK, KO, RI, YI, and GH contributed to patient management. NO was a major contributor to the writing of the manuscript. GK, YY, and TT critically reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Endocrinology and Metabolism, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minamiuonuma, Niigata 949-7302, Japan
(2)
Department of Diabetes, Endocrinology and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
(3)
Department of Respiratory Medicine, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
(4)
Department of Radiology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
(5)
Department of Neurosurgery, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
(6)
Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan

References

  1. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20:812–22.View ArticleGoogle Scholar
  2. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.View ArticleGoogle Scholar
  3. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173–82.View ArticleGoogle Scholar
  4. Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Investig. 2015;38:1159–66.View ArticleGoogle Scholar
  5. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82–92.View ArticleGoogle Scholar
  6. Shang YH, Zhang Y, Li JH, Li P, Zhang X. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. Immunotherapy. 2017;9:261–72.View ArticleGoogle Scholar
  7. Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, Shibusawa N, Shimada T, Higuchi T, Chikamatsu K, Yamada M. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905–12.View ArticleGoogle Scholar
  8. Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017;44:e13–4.View ArticleGoogle Scholar
  9. Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy. J Dermatol. 2017;44:e70.View ArticleGoogle Scholar
  10. Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol. 2017;44:109–10.View ArticleGoogle Scholar
  11. Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, Furue M, Nomura M. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Jpn J Clin Oncol. 2017;47:463–6.View ArticleGoogle Scholar
  12. Cho KY, Miyoshi H, Nakamura A, Kurita T, Atsumi T. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [letter]. Endocr J. 2017;64:235–6.View ArticleGoogle Scholar
  13. Takaya K, Sonoda M, Fuchigami A, Hiyoshi T. Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Intern Med. 2017;56:2463–9.View ArticleGoogle Scholar
  14. Seki T, Yasuda A, Oki M, Kitajima N, Takagi A, Nakajima N, Miyajima A, Fukagawa M. Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma. Tokai J Exp Clin Med. 2017;42:115–20.PubMedGoogle Scholar
  15. Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open. 2017;2:e000217.View ArticleGoogle Scholar
  16. Zeng MF, Chen L, Ye HY, Gong W, Zhou LN, Li YM, Zhao XL. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine (Baltimore). 2017;96:e8426.View ArticleGoogle Scholar
  17. Marchand L, Paulus V, Fabien N, Pérol M, Thivolet C, Vouillarmet J, Saintigny P. Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 2017;12:e182–4.View ArticleGoogle Scholar
  18. Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, Yoneoka Y, Hashimoto T, Hasegawa G, Suzuki K, Takada T. Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review. Intern Med. 2018;57:527–35.View ArticleGoogle Scholar
  19. Takebayashi K, Ujiie A, Kubo M, Furukawa S, Yamauchi M, Shinozaki H, Suzuki T, Naruse R, Hara K, Tsuchiya T, Inukai T. Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma. J Clin Med Res. 2018;10:358–62.View ArticleGoogle Scholar
  20. Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, Iwakura H, Doi N, Yamamoto Y, Akamizu T. Thyrotoxicosis and adrenocortical hormone deficiency during immune-checkpoint inhibitor treatment for malignant melanoma. In Vivo. 2018;32:345–51.PubMedGoogle Scholar
  21. Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 2017;37:4229–32.PubMedGoogle Scholar
  22. Kanie K, Iguchi G, Bando H, Fujita Y, Odake Y, Yoshida K, Matsumoto R, Fukuoka H, Ogawa W, Takahashi Y. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2017;2:91–5.View ArticleGoogle Scholar
  23. Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin deficiency. Pituitary. 2006;9:289–95.View ArticleGoogle Scholar
  24. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.View ArticleGoogle Scholar
  25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–4.View ArticleGoogle Scholar
  26. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390:1550–62.View ArticleGoogle Scholar
  27. Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388:2403–15.View ArticleGoogle Scholar
  28. Lauro S, Onesti CE, Righini R, Marchetti P. The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res. 2014;34:1537–45.PubMedGoogle Scholar
  29. Arrieta O, Zatarain-Barrón ZL, Cardona AF, Carmona A, Lopez-Mejia M. Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin Drug Saf. 2017;16:637–44.View ArticleGoogle Scholar
  30. Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin Endocrinol. 2016;84:372–9.View ArticleGoogle Scholar
  31. O’Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ. Rapid evolution of thyroid dysfunction in patients treated with nivolumab. Endocr Pract. 2017;23:1223–31.View ArticleGoogle Scholar
  32. Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S, Tamiya A, Atagi S. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. In Vivo. 2017;31:1035–9.PubMedGoogle Scholar
  33. Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014;13:412–6.View ArticleGoogle Scholar
  34. Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13:85–9.View ArticleGoogle Scholar
  35. Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T, Iwasaki Y, Kumon Y, Suehiro T, Tanimoto N, Mizobuchi M, Nakamura T. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res. 2005;64:253–60.PubMedGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement